A study to determine the response rate to Inotuzumab-ozogamicin treatment in a population of relapsed B-cell Acute Lymphoblastic Leukemia patients
Latest Information Update: 17 Jul 2020
At a glance
- Drugs Inotuzumab ozogamicin (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 17 Jul 2020 New trial record
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association